Medifast Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Medifast stock.
View analyst ratings for Medifast or view top-rated stocks.

Wall Street analysts have given Medifast a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medifast wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Medifast saw a drop in short interest in the month of January. As of January 29th, there was short interest totaling 423,600 shares, a drop of 23.8% from the January 14th total of 555,900 shares. Based on an average trading volume of 135,100 shares, the days-to-cover ratio is currently 3.1 days. Approximately 3.8% of the shares of the company are sold short.
View Medifast's Short Interest.

Medifast is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Medifast.

Medifast will be holding an earnings conference call on Thursday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Medifast, Inc. (NYSE:MED) announced its quarterly earnings results on Monday, November, 2nd. The specialty retailer reported $2.91 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.49 by $0.42. The specialty retailer earned $271.40 million during the quarter, compared to the consensus estimate of $242.50 million. Medifast had a trailing twelve-month return on equity of 80.07% and a net margin of 11.27%. The business's revenue was up 42.8% on a year-over-year basis. During the same period in the prior year, the company earned $1.32 EPS.
View Medifast's earnings history.

Medifast's stock was trading at $70.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MED stock has increased by 273.9% and is now trading at $263.35.
View which stocks have been most impacted by COVID-19.

Medifast declared a quarterly dividend on Thursday, December 10th. Stockholders of record on Tuesday, December 22nd will be given a dividend of $1.13 per share on Friday, February 5th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 1.72%. The ex-dividend date of this dividend is Monday, December 21st.
View Medifast's dividend history.

Medifast pays an annual dividend of $4.52 per share and currently has a dividend yield of 1.78%. Medifast does not yet have a strock track record of dividend growth. The dividend payout ratio of Medifast is 75.84%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Medifast will have a dividend payout ratio of 43.38% next year. This indicates that Medifast will be able to sustain or increase its dividend.
View Medifast's dividend history.

3 brokerages have issued 1-year target prices for Medifast's shares. Their forecasts range from $239.00 to $300.00. On average, they anticipate Medifast's stock price to reach $268.00 in the next twelve months. This suggests a possible upside of 1.8% from the stock's current price.
View analysts' price targets for Medifast or view top-rated stocks among Wall Street analysts.

44 employees have rated Medifast CEO Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among Medifast's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Medifast include The Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Inter Parfums (IPAR), Prestige Consumer Healthcare (PBH), USANA Health Sciences (USNA), Veru (VERU), Revlon (REV) and Nature's Sunshine Products (NATR).
View all of MED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), The Home Depot (HD), The Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.69%), Renaissance Technologies LLC (8.59%), Rice Hall James & Associates LLC (3.44%), Bank of New York Mellon Corp (1.84%), Principal Financial Group Inc. (1.66%) and Principal Financial Group Inc. (1.66%). Company insiders that own Medifast stock include Carl E Sassano, Jeffrey J Brown, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Rice Hall James & Associates LLC, First Trust Advisors LP, Bank of New York Mellon Corp, Voloridge Investment Management LLC, Principal Financial Group Inc., Principal Financial Group Inc., and Robeco Institutional Asset Management B.V.. Company insiders that have sold Medifast company stock in the last year include Michael C Macdonald, and Scott Schlackman.
View insider buying and selling activity for Medifast or view top insider-selling stocks.

MED stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Lombard Odier Asset Management Switzerland SA, Landscape Capital Management L.L.C., Wells Fargo & Company MN, JPMorgan Chase & Co., Healthcare of Ontario Pension Plan Trust Fund, and Renaissance Technologies LLC.
View insider buying and selling activity for Medifast or or view top insider-buying stocks.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MED stock can currently be purchased for approximately $263.35.

Medifast has a market capitalization of $3.10 billion and generates $713.67 million in revenue each year. The specialty retailer earns $77.92 million in net income (profit) each year or $5.96 on an earnings per share basis.

Medifast employs 550 workers across the globe.

The official website for Medifast is www.medifast1.com.

Medifast is headquartered at 100 International Drive, Baltimore MD, 21202.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]